Zolmitriptan cas: 139264-17-8

CAS NO: 139264-17-8
Zolmitriptan
Description Review
Description

Zolmitriptan (CAS: 139264-17-8) is a medication used for the treatment of migraines. In this article, we will explore the properties, uses, health benefits, potential effects, mechanism, safety, side effects, and dosing information of zolmitriptan.

Introduction: Zolmitriptan is a medication that belongs to the triptan class of drugs, which are commonly used for the treatment of migraines. It works by narrowing blood vessels in the brain and reducing inflammation, thus relieving migraine symptoms such as headache, nausea, and sensitivity to light and sound.

Chemical name: The chemical name of zolmitriptan is 4-((4S)-1-methyl-3-oxo-2-(phenylsulfanyl)methyl)imidazolidin-2-one.

Molecular formula: The molecular formula of zolmitriptan is C16H21N3O2S.

Formula weight: The formula weight of zolmitriptan is 287.43 g/mol.

CAS No: The CAS number for zolmitriptan is 139264-17-8.

Top ten keywords from Google and synonyms:

  • Zolmitriptan
  • Migraine treatment
  • Triptan
  • Vasoconstriction
  • Headache relief
  • Serotonin receptor agonist
  • Acute migraine attack
  • Central nervous system drug
  • Cluster headache
  • 5-HT1B/1D

Health benefits of zolmitriptan: The primary health benefit of zolmitriptan is its ability to effectively relieve migraine symptoms, including headache pain, nausea, and sensitivity to light and sound. By targeting specific receptors in the brain, it can provide rapid and effective relief for patients suffering from acute migraine attacks.

Potential effects: Zolmitriptan works by constricting blood vessels in the brain and reducing inflammation, which can alleviate migraine symptoms. It also acts as an agonist at certain serotonin receptors in the central nervous system, which may contribute to its therapeutic effects.

Product mechanism: The mechanism of action of zolmitriptan is thought to involve its activity as an agonist at the 5-HT1B and 5-HT1D serotonin receptors in the brain. By activating these receptors, it can trigger vasoconstriction and reduce inflammation, which can alleviate migraine symptoms.

Safety: Zolmitriptan is generally safe and well-tolerated when used as directed. However, it may be contraindicated in some patients with certain medical conditions, such as cardiovascular disease or liver impairment. Patients should always discuss their medical history with their healthcare provider before starting zolmitriptan therapy.

Side effects: Common side effects of zolmitriptan use include dizziness, fatigue, and dry mouth. More serious side effects may occur in some patients, such as chest pain, shortness of breath, and severe allergic reactions. Patients should seek medical attention if they experience any of these symptoms.

Dosing information: The optimal dosing regimen for zolmitriptan varies depending on the individual patient and the severity of their symptoms. The medication is typically taken orally, either in tablet or oral disintegrating tablet form. Dosing recommendations range from 2.5 mg to 10 mg per dose, and patients are advised not to exceed more than two doses per day.

Conclusion: Zolmitriptan represents a safe and effective option for the treatment of migraines, offering rapid relief for patients suffering from acute attacks. By targeting specific receptors in the brain, it can effectively narrow blood vessels and reduce inflammation, alleviating symptoms such as headache pain, nausea, and sensitivity to light and sound. While generally well-tolerated, patients should always discuss their medical history with their healthcare provider before starting zolmitriptan therapy and should seek medical attention if they experience any adverse effects.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code